ALK and mature T-cell and NK-cell non-Hodgkin lymphoma: ALK+ sALCL has a better prognosis than ALK– sALCL and other PTCL subtypes [5, 6]; nevertheless, 5-year overall survival (OS) remains 30–50% in older patients with ALK+ sALCL and those with other unfavorable prognostic factors [5, 7].